Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014–2016
暂无分享,去创建一个
Jae Kwan Lee | M. Ki | Jin-Kyoung Oh | K. Min | J. Hong | Y. Ouh | Hyun-Woong Cho | Sangjin Shin
[1] M. Plummer,et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type , 2017, International journal of cancer.
[2] Hongbing Shen,et al. Independent prognostic role of human papillomavirus genotype in cervical cancer , 2017, BMC Infectious Diseases.
[3] Jane J. Kim,et al. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua , 2017, BMJ Open.
[4] G. Krashias,et al. HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities , 2017, BMC Infectious Diseases.
[5] W. Termrungruanglert,et al. A Model Approach for Assessing the Benefits of HPV Testing against Cytology in Screening for Cervical Cancer Precursors in Thailand , 2017, Asian Pacific journal of cancer prevention : APJCP.
[6] K. Jung,et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014 , 2017, Cancer research and treatment : official journal of Korean Cancer Association.
[7] Jae Kwan Lee,et al. Human Papillomavirus Prevalence and Type Distribution Among 968 Women in South Korea , 2016, Journal of cancer prevention.
[8] Kyu-Won Jung,et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013 , 2016, Cancer research and treatment : official journal of Korean Cancer Association.
[9] J. Cuzick. Gardasil 9 joins the fight against cervix cancer , 2015, Expert review of vaccines.
[10] C. Cho,et al. The Korean guideline for cervical cancer screening , 2015, Journal of gynecologic oncology.
[11] M. Karlsson,et al. Evaluation of HPV Genotyping Assays for Archival Clinical Samples. , 2015, The Journal of molecular diagnostics : JMD.
[12] J. Cuzick,et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.
[13] E. J. Mayeaux,et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. , 2015, Gynecologic oncology.
[14] S. Rosini,et al. Clinical Interventions in Aging Dovepress , 2022 .
[15] M. Kwon,et al. Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[16] T. Iftner,et al. Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? , 2014, Cancer Causes & Control.
[17] R. Sahli,et al. Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV Assay for Human Papillomavirus Genotyping , 2013, Journal of Clinical Microbiology.
[18] J. Monsonego,et al. Prévalence des génotypes d’HPV chez les femmes en France : implications pour le dépistage et la vaccination , 2013 .
[19] Sunmie Kim,et al. Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women , 2013, Obstetrics & gynecology science.
[20] M. Plummer,et al. Global burden of human papillomavirus and related diseases. , 2012, Vaccine.
[21] N. Muñoz,et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.
[22] Sung Soon Kim,et al. Prevalence of human papillomavirus infection and genotype distribution among high-risk Korean women for prospecting the strategy of vaccine development , 2010, Virology Journal.
[23] E. Armstrong,et al. Prophylaxis of Cervical Cancer and Related Cervical Disease: A Review of the Cost-Effectiveness of Vaccination Against Oncogenic HPV Types , 2010, Journal of managed care pharmacy : JMCP.
[24] Joakim Dillner,et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. , 2010, Journal of the National Cancer Institute.
[25] S. Hur,et al. Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis. , 2008, Journal of microbiology and biotechnology.
[26] T. Hwang,et al. Clinical Efficacy of Human Papillomavirus DNA Detection in Urine from Patients with Various Cervical Lesions , 2007, Journal of Korean medical science.
[27] J. Nam,et al. Human papillomavirus genotyping using HPV DNA chip analysis in Korean women , 2006, International Journal of Gynecologic Cancer.
[28] S. Franceschi,et al. Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.
[29] S. Franceschi,et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. , 2004, The Journal of infectious diseases.
[30] U. Liebert,et al. PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[31] Mark Sherman,et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.
[32] K. Syrjänen,et al. [Prevalence of genotype-specific HPV infection among women in France: implications for screening and vaccination]. , 2013, Gynécologie Obstétrique & Fertilité.
[33] Leslie Carol Botha. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial , 2010 .
[34] F. X. Bosch,et al. Type-specific human papillomavirus distribution in invasive cervical cancer in Korea, 1958-2004. , 2010, Asian Pacific journal of cancer prevention : APJCP.